ClinicalTrials.Veeva

Menu
S

Sooner Clinical Research | Oklahoma City, OK

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Cariprazine
Rapastinel
Pregabalin
SPD489
Dapagliflozin
Balsalazide Disodium
Eslicarbazepine Acetate
BI 1569912
Lyrica
ABBV-932

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 61 total trials

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT)

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Active, not recruiting
Depressive Disorder, Major
Drug: Aticaprant

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling
Bipolar I Disorder
Depression
Drug: Placebo
Drug: Cariprazine

Demonstrate ability of SEP-363856 to be superior to placebo as an adjunctive therapy to ADT in change from baseline in depressive symptoms (MADRS \&...

Active, not recruiting
Major Depressive Disorder
Other: Placebo
Drug: SEP-363856

The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The mai...

Enrolling
Major Depressive Disorder
Drug: Zelquistinel

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how saf...

Enrolling
Bipolar II Disorder
Bipolar I Disorder
Drug: Placebo for ABBV-932
Drug: ABBV-932

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately t...

Enrolling
Generalized Anxiety Disorder (GAD)
Drug: Antidepressant Therapy (ADT)
Drug: ABBV-932

The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive...

Enrolling
Major Depressive Disorder (MDD)
Drug: Ropanicant
Drug: Placebo

Trial sponsors

AbbVie logo
Sumitomo Pharma logo
Viatris logo
Otsuka logo
Allergan logo
Janssen (J&J Innovative Medicine) logo
Bausch Health logo
Allergan logo
AstraZeneca logo
Boehringer Ingelheim logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems